MyFinsight
Home
Blog
About
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,300,271
Unit: Dollar
Positive Cash Flow Breakdown
Accounts payable
Prepaid expenses and other curre...
Proceeds from exercise of common...
Negative Cash Flow Breakdown
Net loss
Accrued expenses and other curre...
Proceeds from issuance of common...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,447,831
-3,195,987
-3,367,679
-4,010,773
Change in fair value of warrant liabilities
0
0
-44,506
27,816
Stock-based compensation expense
214,565
584,439
455,084
458,379
Prepaid clinical trial costs (current and non-current)
30,000
0
-81,742
-22,705
Prepaid expenses and other current assets
-148,775
-36,251
416,758
-99,037
Accounts payable
278,451
-976,347
-2,197,246
325,332
Accrued expenses and other current liabilities
-279,362
-249,652
-308,848
-2,511,982
Net cash used in operating activities
-2,115,402
-3,801,296
-5,798,211
-5,589,486
Proceeds from issuance of short-term debt
-
-
406,875
0
Repayment of short-term debt
87,181
175,601
0
113,246
Proceeds from issuance of common stock in atm offering, net of transaction costs-The Market Offering Agreement Atm Agreement
-3,891
2,535,337
176,721
312,574
Proceeds from issuance of common stock, common stock warrants, and prefunded warrants in offerings, net of transaction costs paid
-93,827
9,192,991
-264,792
8,209,703
Proceeds from exercise of common stock warrants-Common Stock Warrants
30
8
6,734,940
0
Net cash provided by financing activities
-184,869
11,552,735
7,053,744
8,409,031
Net increase (decrease) in cash and cash equivalents
-2,300,271
7,751,439
1,255,533
2,819,545
Cash and cash equivalents, beginning of period
22,190,231
14,438,792
13,183,259
13,476,331
Cash and cash equivalents, end of period
19,889,960
22,190,231
14,438,792
13,183,259
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$2,300,271
(26.10%↑ Y/Y)
Accounts payable
$278,451
(118.13%↑ Y/Y)
Stock-based compensation
expense
$214,565
(-83.68%↓ Y/Y)
Prepaid expenses and
other current assets
-$148,775
(53.43%↑ Y/Y)
Proceeds from exercise of
common stock...
$30
(-99.99%↓ Y/Y)
Net cash used in
operating activities
-$2,115,402
(83.98%↑ Y/Y)
Net cash provided by
financing activities
-$184,869
(-101.83%↓ Y/Y)
Canceled cashflow
$641,791
Canceled cashflow
$30
Net loss
-$2,447,831
(80.40%↑ Y/Y)
Proceeds from issuance of
common stock, common...
-$93,827
(-101.02%↓ Y/Y)
Repayment of short-term
debt
$87,181
(-74.72%↓ Y/Y)
Proceeds from issuance of
common stock in atm...
-$3,891
(-100.39%↓ Y/Y)
Accrued expenses and
other current...
-$279,362
(76.37%↑ Y/Y)
Prepaid clinical trial
costs (current and...
$30,000
(106.88%↑ Y/Y)
Buy us a coffee